Baillie Gifford & Co. Cuts Stock Position in Twist Bioscience Co. (NASDAQ:TWST)

Baillie Gifford & Co. lowered its position in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 6.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 777,537 shares of the company's stock after selling 56,802 shares during the period. Baillie Gifford & Co. owned 1.31% of Twist Bioscience worth $36,132,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the company. State Street Corp grew its stake in Twist Bioscience by 19.9% during the third quarter. State Street Corp now owns 3,167,353 shares of the company's stock valued at $143,101,000 after acquiring an additional 526,028 shares in the last quarter. Geode Capital Management LLC grew its stake in Twist Bioscience by 1.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,367,759 shares of the company's stock worth $61,807,000 after buying an additional 26,145 shares in the last quarter. Thrivent Financial for Lutherans purchased a new position in Twist Bioscience in the 3rd quarter worth approximately $43,992,000. Wellington Management Group LLP grew its stake in Twist Bioscience by 188.5% in the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company's stock worth $36,042,000 after buying an additional 521,272 shares in the last quarter. Finally, Fred Alger Management LLC grew its stake in Twist Bioscience by 17.1% in the 3rd quarter. Fred Alger Management LLC now owns 767,149 shares of the company's stock worth $34,660,000 after buying an additional 112,272 shares in the last quarter.

Insider Transactions at Twist Bioscience

In other news, CFO Adam Laponis sold 5,886 shares of the firm's stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $43.26, for a total transaction of $254,628.36. Following the sale, the chief financial officer now owns 110,096 shares of the company's stock, valued at $4,762,752.96. This trade represents a 5.07 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Robert Chess sold 2,940 shares of the firm's stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $53.13, for a total transaction of $156,202.20. Following the sale, the director now directly owns 18,173 shares in the company, valued at approximately $965,531.49. The trade was a 13.93 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 37,180 shares of company stock valued at $1,821,971 in the last three months. 3.01% of the stock is currently owned by company insiders.

Twist Bioscience Trading Down 8.4 %

NASDAQ:TWST traded down $3.77 during midday trading on Friday, reaching $41.31. 1,566,739 shares of the stock traded hands, compared to its average volume of 872,724. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96. Twist Bioscience Co. has a 12 month low of $27.41 and a 12 month high of $60.90. The stock has a market capitalization of $2.46 billion, a P/E ratio of -12.22 and a beta of 1.87. The company has a fifty day moving average of $48.10 and a 200 day moving average of $45.75.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The business had revenue of $88.70 million during the quarter, compared to analyst estimates of $86.96 million. During the same period in the prior year, the business earned ($0.75) EPS. The company's revenue for the quarter was up 24.1% on a year-over-year basis. On average, research analysts predict that Twist Bioscience Co. will post -2.12 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on TWST shares. Scotiabank boosted their price target on shares of Twist Bioscience from $54.00 to $62.00 and gave the stock a "sector outperform" rating in a research note on Tuesday, February 4th. Wolfe Research began coverage on shares of Twist Bioscience in a research note on Friday, December 13th. They issued an "outperform" rating and a $60.00 price objective for the company. TD Cowen reaffirmed a "buy" rating and issued a $58.00 price objective on shares of Twist Bioscience in a research note on Tuesday, November 26th. JPMorgan Chase & Co. upped their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a research note on Tuesday, February 4th. Finally, Robert W. Baird upped their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a report on Tuesday, February 4th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $53.80.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.